美国退伍军人冠心病患者优化他汀与依折麦布治疗的预测结局
这项观察性队列研究纳入2015年6月至2020年9月在全美82家退伍军人事务部医疗机构经冠状动脉造影确诊冠心病的111954名退伍军人,评估实际降脂治疗、优化他汀方案及优化他汀联合依折麦布三种暴露。6个月时仅52.9%使用高强度他汀、1.1%使用依折麦布,52.1%患者LDL-C≥70 mg/dL。4年实际死亡、心肌梗死、卒中、冠状动脉血运重建发生率分别为21.6%、5.0%、2.2%、15.4%;预测优化他汀可使上述事件绝对下降1.3%、0.8%、0.2%、2.3%,联合依折麦布进一步降至1.8%、1.1%、0.3%、3.1%。作者认为优化他汀治疗可产生有临床意义的死亡和心血管事件风险降低,依折麦布虽降脂效力较弱,但在人群层面广泛联合优化他汀可能带来进一步有意义的心血管风险下降。
要点
- 6个月时仅57 297例(52.9%)使用高强度他汀、1 168例(1.1%)使用依折麦布,56 405例(52.1%)LDL-C≥70 mg/dL。
- 4年实际死亡21.6%(95%CI 21.3%-21.8%)、心肌梗死5.0%(95%CI 4.9%-5.2%)、卒中2.2%(95%CI 2.1%-2.3%)、血运重建15.4%(95%CI 15.2%-15.7%)。
- 预测优化他汀使死亡绝对下降1.3%(95%CI 0.9%-1.7%)、心肌梗死0.8%(95%CI 0.7%-1.0%)、卒中0.2%(95%CI 0.1%-0.3%)、血运重建2.3%(95%CI 2.0%-2.7%)。
- 预测优化他汀联合依折麦布使死亡绝对下降1.8%(95%CI 1.2%-2.4%)、心肌梗死1.1%(95%CI 0.9%-1.3%)、卒中0.3%(95%CI 0.2%-0.4%)、血运重建3.1%(95%CI 2.6%-3.6%)。
- 作者认为优化他汀治疗可产生有临床意义的死亡和心血管事件风险降低,依折麦布在人群层面联合优化他汀可能带来进一步有意义的心血管风险下降。
适用人群与场景
- 2015年6月至2020年9月在全美82家美国退伍军人事务部医疗机构经冠状动脉造影确诊冠心病的美国退伍军人。
- 队列111 954例,平均(SD)年龄68.4(8.8)岁,男性109 390例(97.7%),白人91 589例(81.8%),黑人17 592例(15.7%)。
研究设计与关键结果
- 观察性队列研究,纳入111 954例冠心病退伍军人,观察期中位数(IQR)3.4(2.1-4.0)年。
- 造影时66 877例(59.7%)接受他汀治疗、623例(0.6%)接受依折麦布;6个月时他汀处方增至74 400例(68.7%),高强度他汀仅57 297例(52.9%),依折麦布1 168例(1.1%),LDL-C≥70 mg/dL者56 405例(52.1%)。
- 4年实际死亡21.6%(95%CI 21.3%-21.8%)、心肌梗死5.0%(95%CI 4.9%-5.2%)、卒中2.2%(95%CI 2.1%-2.3%)、冠状动脉血运重建15.4%(95%CI 15.2%-15.7%)。
- 优化他汀预测绝对下降:死亡1.3%(95%CI 0.9%-1.7%)、心肌梗死0.8%(95%CI 0.7%-1.0%)、卒中0.2%(95%CI 0.1%-0.3%)、血运重建2.3%(95%CI 2.0%-2.7%)。
- 优化他汀联合依折麦布预测绝对下降:死亡1.8%(95%CI 1.2%-2.4%)、心肌梗死1.1%(95%CI 0.9%-1.3%)、卒中0.3%(95%CI 0.2%-0.4%)、血运重建3.1%(95%CI 2.6%-3.6%)。
证据类型、等级与局限
- 证据类型:观察性队列研究(JAMA Netw Open)。
- 预测基于胆固醇治疗试验者协作组(The Cholesterol Treatment Trialists' Collaboration)公式及LDL-C预期进一步下降推算。
对床旁实践的改变
- 作者认为优化他汀治疗可产生有临床意义的死亡和心血管事件风险降低。
- 作者认为依折麦布虽降脂效力较弱,但在人群层面广泛联合优化他汀治疗可能带来进一步有意义的心血管风险下降。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Many patients with coronary artery disease (CAD) do not achieve the guideline-directed goals for low-density lipoprotein cholesterol (LDL-C) levels.
OBJECTIVE: To estimate reductions in the rates of adverse events associated with CAD in a large US military veteran population that may be achieved through use of optimized statin therapy alone or with ezetimibe compared with the prevailing lipid-lowering therapy (LLT).
DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, US military veterans with CAD were identified by coronary angiography between June 2015 and September 2020 across 82 US Department of Veterans Affairs health care facilities.
EXPOSURES: The exposures were observed LLT, LLT with an optimized statin regimen, and LLT with optimized statin and ezetimibe.
MAIN OUTCOMES AND MEASURES: Observed rates of death, myocardial infarction, stroke, and coronary revascularization, and potential reductions in those outcomes with optimized LLT based on expected further reductions in LDL-C levels and application of formulas from The Cholesterol Treatment Trialists' Collaboration.
RESULTS: The analysis cohort comprised 111 954 veterans (mean [SD] age, 68.4 [8.8] years; 109 390 men [97.7%]; 91 589 White patients [81.8%]; 17 592 Black patients [15.7%]). The median (IQR) observation period for this study was 3.4 (2.1-4.0) years. At the time of index angiography, 66 877 patients (59.7%) were treated with statin therapy, and 623 patients (0.6%) were treated with ezetimibe. At 6 months, the number of patients with statin prescriptions increased to 74 400 (68.7%), but the number of patients with high-intensity statin prescriptions was only 57 297 (52.9%). At 6 months, ezetimibe use remained low (n = 1168 [1.1%]), and LDL-C levels were 70 mg/dL or more in 56 405 patients (52.1%). At 4 years, observed incidences of death, myocardial infarction, stroke, and coronary revascularization were 21.6% (95% CI, 21.3%-21.8%), 5.0% (95% CI, 4.9%-5.2%), 2.2% (95% CI, 2.1%-2.3%), and 15.4% (95% CI, 15.2%-15.7%), respectively. With optimized statin treatment, projected absolute reductions in these incidences were 1.3% (95% CI, 0.9%-1.7%), 0.8% (95% CI, 0.7%-1.0%), 0.2% (95% CI, 0.1%-0.3%), and 2.3% (95% CI, 2.0%-2.7%), respectively. With optimized statin and ezetimibe treatment, projected absolute reductions were 1.8% (95% CI, 1.2%-2.4%), 1.1% (95% CI, 0.9%-1.3%), 0.3% (95% CI, 0.2%-0.4%), and 3.1% (95% CI, 2.6%-3.6%), respectively.
CONCLUSIONS AND RELEVANCE: In this cohort study of veterans with CAD, suboptimal LLT was prevalent in the clinical setting. Optimization of statin therapy was projected to produce clinically relevant reductions in the risks of death and cardiovascular events. Despite a lesser lipid-lowering efficacy of ezetimibe, its widespread use on a population level in conjunction with optimized statin therapy may be associated with further meaningful reductions in cardiovascular risk.
参考来源
- Kovach CP, Mesenbring EC, Gupta P, et al. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease. JAMA Netw Open. 2023. PMID: 37638630. doi:10.1001/jamanetworkopen.2023.29066
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。